墨西哥小儿Vogt-Koyanagi-Harada病的临床特征、复发和并发症

IF 2.6 4区 医学 Q2 OPHTHALMOLOGY
Luz Elena Concha-Del-Rio, Diego Ivan Cervera-Ruiz, Ronald Rivera-Sempértegui
{"title":"墨西哥小儿Vogt-Koyanagi-Harada病的临床特征、复发和并发症","authors":"Luz Elena Concha-Del-Rio, Diego Ivan Cervera-Ruiz, Ronald Rivera-Sempértegui","doi":"10.1080/09273948.2025.2495078","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>To analyze the clinical characteristics, number of recurrences, and complications in the Mexican pediatric patients with Vogt-Koyanagi-Harada (VKH) disease.</p><p><strong>Methods: </strong>A retrospective review of pediatric patients aged 16 years and under, diagnosed with VKH, was conducted from January 1988 to February 2023 at Asociación para Evitar la Ceguera en México I.A.P.</p><p><strong>Results: </strong>Thirty-one patients (<i>n</i> = 62 eyes), with a diagnosis of VKH were identified, with a mean age of 12.06   ±   3.57 years. Follow-up was 7.22   ±   6.85 years. At initial presentation, the best-corrected visual acuity (BCVA) was 1.31   ±   0.94 LogMAR (Snellen 20/400) and final 0.5   ±   0.93 LogMAR (Snellen 20/60) (<i>p</i> = 0.001). The most common clinical findings in the uveitic stage were anterior chamber inflammation (70%) and serous retinal detachment (72%). The treatment approach involved a combination of oral steroids, intravenous steroids, and immunomodulatory agents. Despite the initial visual impairment, most patients achieved disease remission. However, 41.93% of the patients experienced at least one recurrence during follow-up. The most frequent complications were sunset-glow fundus 74.19% (<i>n</i> = 46 eyes), and glaucoma 27.41% (<i>n</i> = 17 eyes).</p><p><strong>Conclusion: </strong>VKH disease in the Mexican pediatric patients has proved to be a challenge in management due to its aggressive course. Timely diagnosis and treatment with steroid therapy associated with a systemic immunomodulatory are essential to reduce recurrences, and complications and thus have a better visual prognosis.</p>","PeriodicalId":19406,"journal":{"name":"Ocular Immunology and Inflammation","volume":" ","pages":"1-10"},"PeriodicalIF":2.6000,"publicationDate":"2025-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Clinical Characteristics, Recurrences, and Complications in the Mexican Pediatric Patients with Vogt-Koyanagi-Harada Disease.\",\"authors\":\"Luz Elena Concha-Del-Rio, Diego Ivan Cervera-Ruiz, Ronald Rivera-Sempértegui\",\"doi\":\"10.1080/09273948.2025.2495078\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>To analyze the clinical characteristics, number of recurrences, and complications in the Mexican pediatric patients with Vogt-Koyanagi-Harada (VKH) disease.</p><p><strong>Methods: </strong>A retrospective review of pediatric patients aged 16 years and under, diagnosed with VKH, was conducted from January 1988 to February 2023 at Asociación para Evitar la Ceguera en México I.A.P.</p><p><strong>Results: </strong>Thirty-one patients (<i>n</i> = 62 eyes), with a diagnosis of VKH were identified, with a mean age of 12.06   ±   3.57 years. Follow-up was 7.22   ±   6.85 years. At initial presentation, the best-corrected visual acuity (BCVA) was 1.31   ±   0.94 LogMAR (Snellen 20/400) and final 0.5   ±   0.93 LogMAR (Snellen 20/60) (<i>p</i> = 0.001). The most common clinical findings in the uveitic stage were anterior chamber inflammation (70%) and serous retinal detachment (72%). The treatment approach involved a combination of oral steroids, intravenous steroids, and immunomodulatory agents. Despite the initial visual impairment, most patients achieved disease remission. However, 41.93% of the patients experienced at least one recurrence during follow-up. The most frequent complications were sunset-glow fundus 74.19% (<i>n</i> = 46 eyes), and glaucoma 27.41% (<i>n</i> = 17 eyes).</p><p><strong>Conclusion: </strong>VKH disease in the Mexican pediatric patients has proved to be a challenge in management due to its aggressive course. Timely diagnosis and treatment with steroid therapy associated with a systemic immunomodulatory are essential to reduce recurrences, and complications and thus have a better visual prognosis.</p>\",\"PeriodicalId\":19406,\"journal\":{\"name\":\"Ocular Immunology and Inflammation\",\"volume\":\" \",\"pages\":\"1-10\"},\"PeriodicalIF\":2.6000,\"publicationDate\":\"2025-05-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Ocular Immunology and Inflammation\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/09273948.2025.2495078\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"OPHTHALMOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ocular Immunology and Inflammation","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/09273948.2025.2495078","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

目的:分析墨西哥小儿Vogt-Koyanagi-Harada (VKH)病的临床特点、复发率及并发症。方法:回顾性分析1988年1月至2023年2月在Asociación para Evitar la Ceguera en m xico i.a.p.p诊断为VKH的16岁及以下儿童患者。结果:确诊为VKH的31例(n = 62眼),平均年龄为12.06±3.57岁。随访时间为7.22±6.85年。初诊时最佳矫正视力(BCVA)为1.31±0.94 LogMAR (Snellen 20/400),终诊时为0.5±0.93 LogMAR (Snellen 20/60) (p = 0.001)。葡萄膜期最常见的临床表现是前房炎症(70%)和浆液性视网膜脱离(72%)。治疗方法包括口服类固醇、静脉注射类固醇和免疫调节剂的组合。尽管最初出现了视力障碍,但大多数患者都获得了疾病缓解。然而,41.93%的患者在随访期间至少有一次复发。最常见的并发症是晚霞眼底(74.19%)和青光眼(27.41%)(n = 17)。结论:墨西哥儿童的VKH疾病由于其病程的侵袭性,已被证明是一个管理上的挑战。及时诊断和治疗类固醇治疗与全身免疫调节是必不可少的,以减少复发和并发症,从而有更好的视力预后。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Clinical Characteristics, Recurrences, and Complications in the Mexican Pediatric Patients with Vogt-Koyanagi-Harada Disease.

Purpose: To analyze the clinical characteristics, number of recurrences, and complications in the Mexican pediatric patients with Vogt-Koyanagi-Harada (VKH) disease.

Methods: A retrospective review of pediatric patients aged 16 years and under, diagnosed with VKH, was conducted from January 1988 to February 2023 at Asociación para Evitar la Ceguera en México I.A.P.

Results: Thirty-one patients (n = 62 eyes), with a diagnosis of VKH were identified, with a mean age of 12.06   ±   3.57 years. Follow-up was 7.22   ±   6.85 years. At initial presentation, the best-corrected visual acuity (BCVA) was 1.31   ±   0.94 LogMAR (Snellen 20/400) and final 0.5   ±   0.93 LogMAR (Snellen 20/60) (p = 0.001). The most common clinical findings in the uveitic stage were anterior chamber inflammation (70%) and serous retinal detachment (72%). The treatment approach involved a combination of oral steroids, intravenous steroids, and immunomodulatory agents. Despite the initial visual impairment, most patients achieved disease remission. However, 41.93% of the patients experienced at least one recurrence during follow-up. The most frequent complications were sunset-glow fundus 74.19% (n = 46 eyes), and glaucoma 27.41% (n = 17 eyes).

Conclusion: VKH disease in the Mexican pediatric patients has proved to be a challenge in management due to its aggressive course. Timely diagnosis and treatment with steroid therapy associated with a systemic immunomodulatory are essential to reduce recurrences, and complications and thus have a better visual prognosis.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
6.20
自引率
15.20%
发文量
285
审稿时长
6-12 weeks
期刊介绍: Ocular Immunology & Inflammation ranks 18 out of 59 in the Ophthalmology Category.Ocular Immunology and Inflammation is a peer-reviewed, scientific publication that welcomes the submission of original, previously unpublished manuscripts directed to ophthalmologists and vision scientists. Published bimonthly, the journal provides an international medium for basic and clinical research reports on the ocular inflammatory response and its control by the immune system. The journal publishes original research papers, case reports, reviews, letters to the editor, meeting abstracts, and invited editorials.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信